Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8100059 | 0.98 | SIGMAR1 (0.67) | L3MBTL1ALDH1A1MAPTSIGMAR1HPGD | |
| SCHEMBL1334972 | 0.93 | L3MBTL1 (0.72) | L3MBTL1ALDH1A1MAPTSIGMAR1HPGD | |
| Oxalic Acid SCHEMBL9374016 | 0.89 | TRPV1 (0.57) | L3MBTL1ALDH1A1MAPTSIGMAR1KMT2A | |
| SCHEMBL28511931 | 0.88 | SIGMAR1 (0.55) | L3MBTL1ALDH1A1MAPTSIGMAR1KMT2A | |
| SCHEMBL7835635 | 0.87 | SIGMAR1 (0.53) | L3MBTL1ALDH1A1MAPTSIGMAR1HPGD | |
| SCHEMBL6191025 | 0.87 | KCNH3 (0.58) | L3MBTL1ALDH1A1MAPTSIGMAR1HPGD | |
| SCHEMBL7838071 | 0.87 | SIGMAR1 (0.53) | L3MBTL1ALDH1A1MAPTSIGMAR1HPGD | |
| SCHEMBL11791367 | 0.87 | MAOB (0.66) | L3MBTL1ALDH1A1MAPTSIGMAR1KMT2A | |
| SCHEMBL4970157 | 0.86 | ALDH1A1 (0.89) | L3MBTL1ALDH1A1MAPT | |
| SCHEMBL295159 | 0.85 | MAOB (0.63) | L3MBTL1ALDH1A1MAPTSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767690-B2 | Amino alcohol derivatives and their use as renin inhibitor | NOVARTIS AG (CH) | 2010-08-03 | — | — | US | disclosed |
| US-20090118281-A1 | Amino Alcohol Derivatives And Their Use As Renin Inhibitor | NOVARTIS AG (CH) | 2009-05-07 | — | — | US | disclosed |
| US-20070021400-A1 | Amino alcohols as therapeutic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-01-25 | — | — | US | disclosed |
| EP-1745776-A1 | Aminoalcohols as therapeutic compounds | Speedel Experimenta AG (CH) | 2007-01-24 | — | — | EP | disclosed |
| EP-1711456-A2 | AMINO ALCOHOL DERIVATIVES AND THEIR USE AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005070870-A2 | AMINO ALCOHOL DERIVATIVES AND THEIR USE AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2005-08-04 | — | — | WO | disclosed |
| WO-1998037084-A1 | 3-SUBSTITUTED CLAVAMS FOR CALPAIN INHIBITION | SMITHKLINE BEECHAM CORPORATION (US) | 1998-08-27 | — | — | WO | disclosed |
| US-5719141-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0702004-A2 | 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxy-alkanoic acid amid derivatives | CIBA-GEIGY AG (CH) | 1996-03-20 | — | — | EP | disclosed |
| US-4734490-A | TEXTILE DYEING AND PRINTING | CIBA-GEIGY CORPORATION (US) | 1988-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118281-A1 | Amino Alcohol Derivatives And Their Use As Renin Inhibitor | REN, AGTR1, ADH1A | L3MBTL1 3039/4885ALDH1A1 161/4885MAPT 2542/4885 |
| US-20070021400-A1 | Amino alcohols as therapeutic compounds | CTSL, CTSD, CTSS | L3MBTL1 481/4885ALDH1A1 279/4885MAPT 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.